Use of cyclo‐oxygenase 2 inhibitors (COX‐2) and prescription non‐steroidal anti‐inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX‐2 cardiovascular profile

COX‐2 and NSAIDS differ in their gastrointestinal (GI) and cardiovascular (CV) toxicity from pharmacological, clinical and epidemiologic point of views.

[1]  A. Laupacis,et al.  Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study , 2004, The Lancet.

[2]  Sonia Hernández-Díaz,et al.  Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. , 2006, Basic & clinical pharmacology & toxicology.

[3]  Peter Jüni,et al.  Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? , 2002, BMJ : British Medical Journal.

[4]  S. Hernández-Díaz,et al.  Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. , 2000, Archives of internal medicine.

[5]  H. Leufkens,et al.  The trade‐off between cardiovascular and gastrointestinal effects of rofecoxib , 2005, Pharmacoepidemiology and drug safety.

[6]  H. Krum,et al.  Demographics and concomitant disorders in heart failure , 2003, The Lancet.

[7]  A. McCaddon,et al.  Effect of supplementation with folic-acid on relation between plasma homocysteine, folate, and vitamin B12 , 2002, The Lancet.

[8]  F. Ahern,et al.  Gender Differences in NSAID Use among Older Adults with Osteoarthritis , 2003, The Annals of pharmacotherapy.

[9]  L. Laine,et al.  Utilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysis. , 2004, The American journal of medicine.

[10]  James M Brophy,et al.  The Risk for Myocardial Infarction With Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults , 2005, Annals of internal medicine.

[11]  D. Henry,et al.  Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. , 2000, Archives of internal medicine.

[12]  Marc A Pfeffer,et al.  Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005, The New England journal of medicine.

[13]  A. Laupacis,et al.  COX-2 inhibitors and risk of heart failure , 2004, The Lancet.

[14]  Jeffrey M Drazen,et al.  COX-2 inhibitors--a lesson in unexpected problems. , 2005, The New England journal of medicine.

[15]  C. Mullins,et al.  Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. , 2005, Archives of internal medicine.

[16]  S. Hernández-Díaz,et al.  The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents , 2000, Arthritis Research & Therapy.

[17]  R. Huupponen,et al.  Heavy users of non-steroidal anti-inflammatory drugs: a nationwide prescription database study in Finland , 2003, European Journal of Clinical Pharmacology.

[18]  M. Reilly,et al.  Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction , 2005, Annals of Internal Medicine.

[19]  R Day,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[20]  Carol Coupland,et al.  Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis , 2005, BMJ : British Medical Journal.

[21]  Robert Riddell,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[22]  Sebastian Schneeweiss,et al.  Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults , 2004, Circulation.

[23]  R. Vasan,et al.  The progression from hypertension to congestive heart failure. , 1996, JAMA.

[24]  K. Wells,et al.  The impact of NSAID or COX‐2 inhibitor use on the initiation of antihypertensive therapy , 2006, Pharmacoepidemiology and drug safety.

[25]  R. Tarone,et al.  Risks of Hospitalization for Myocardial Infarction Among Users of Rofecoxib, Celecoxib, and Other NSAIDs , 2005 .

[26]  R. Stafford,et al.  National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. , 2005, Archives of internal medicine.

[27]  Andreas Hoeft,et al.  Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. , 2005, The New England journal of medicine.

[28]  Carolyn C Cannuscio,et al.  Cardiovascular risk of selective cyclooxygenase‐2 inhibitors and other non‐aspirin non‐steroidal anti‐inflammatory medications , 2006, Pharmacoepidemiology and drug safety.

[29]  C Michael Stein,et al.  COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease , 2002, The Lancet.

[30]  S. Hernández-Díaz,et al.  Relative Risk of Upper Gastrointestinal Complications among Users of Acetaminophen and Nonsteroidal Anti-Inflammatory Drugs , 2001, Epidemiology.

[31]  S. Hill,et al.  Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis , 1996, BMJ.

[32]  V. Wong,et al.  Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. , 2002, The New England journal of medicine.

[33]  Peter C Austin,et al.  Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. , 2003, Archives of internal medicine.

[34]  K. Bennett,et al.  "Selective" switching from non-selective to selective non-steroidal anti-inflammatory drugs , 2003, European Journal of Clinical Pharmacology.

[35]  M. Wallander,et al.  Incidence of newly diagnosed heart failure in UK general practice , 2001, European journal of heart failure.

[36]  S. Shoor,et al.  Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study , 2005, The Lancet.

[37]  S. Hernández-Díaz,et al.  Nonsteroidal Antiinflammatory Drugs as a Trigger of Clinical Heart Failure , 2003, Epidemiology.

[38]  T. MacDonald,et al.  Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs , 2003, Gut.

[39]  Y. Moride,et al.  Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec. , 2003, Rheumatology.

[40]  H. Sørensen,et al.  Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. , 2005, Archives of internal medicine.

[41]  E H Wagner,et al.  A chronic disease score from automated pharmacy data. , 1992, Journal of clinical epidemiology.

[42]  M. Wolfe,et al.  Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. , 1999, The New England journal of medicine.